EA201101162A1 - DERIVATIVES OF BICYCLIC AMIDA FOR STRENGTHENING GLUTAMATERGIC SYNAPTIC RESPONSES - Google Patents

DERIVATIVES OF BICYCLIC AMIDA FOR STRENGTHENING GLUTAMATERGIC SYNAPTIC RESPONSES

Info

Publication number
EA201101162A1
EA201101162A1 EA201101162A EA201101162A EA201101162A1 EA 201101162 A1 EA201101162 A1 EA 201101162A1 EA 201101162 A EA201101162 A EA 201101162A EA 201101162 A EA201101162 A EA 201101162A EA 201101162 A1 EA201101162 A1 EA 201101162A1
Authority
EA
Eurasian Patent Office
Prior art keywords
syndrome
brain
diseases
sleep apnea
compounds
Prior art date
Application number
EA201101162A
Other languages
Russian (ru)
Other versions
EA018994B1 (en
Inventor
Рудольф Мюллер
Лесли Дж. Стрит
Original Assignee
Кортекс Фармасеутикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кортекс Фармасеутикалс, Инк. filed Critical Кортекс Фармасеутикалс, Инк.
Publication of EA201101162A1 publication Critical patent/EA201101162A1/en
Publication of EA018994B1 publication Critical patent/EA018994B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Abstract

Настоящее изобретение относится к соединениям, фармацевтическим композициям и способам для использования в профилактике и лечении церебральной недостаточности, включая усиление функционирования рецепторов в синапсах в мозговых сетях, отвечающих за поведение низшего и высшего порядка. Указанные мозговые сети участвуют в регулировании когнитивных способностей, связанных с расстройствами памяти, такими как наблюдаемыми при различных формах слабоумия, при дисбалансе неврональной активности между различными областями мозга, на что указывают такие заболевания, как болезнь Паркинсона, шизофрения, приступы апноэ во время сна, синдром дефицита внимания с гиперактивностью и аффективное расстройство, или расстройство настроения, и при заболеваниях, при которых возникает дефицит нейротрофических факторов, а также при таких заболеваниях, как синдром центрального апноэ сна, вызванного инсультом, синдром обструктивного апноэ сна, синдром врожденной гиповентиляции, синдром гиповентиляции вследствие ожирения, синдром внезапной смерти внешне здорового ребёнка, синдром Ретта, повреждения спинного мозга, травматическое повреждение головного мозга, дыхание Чейна-Стокса, центральный врождённый гиповентиляционный синдром, синдром Прадера-Вилли и смерть мозга. В частности, изобретение относится к бициклическим амидным соединениям, применяемым для лечения указанных состояний и способам использования указанных соединений для проведения такого лечения.The present invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancing the functioning of receptors in synapses in brain networks responsible for lower and higher order behavior. These brain networks are involved in the regulation of cognitive abilities associated with memory disorders, such as those observed in various forms of dementia, with an imbalance of neuronal activity between different areas of the brain, as indicated by diseases such as Parkinson's disease, schizophrenia, sleep apnea, syndrome attention deficit hyperactivity disorder and affective disorder, or mood disorder, and in diseases in which there is a deficit of neurotrophic factors, as well as in diseases like central sleep apnea caused by stroke, obstructive sleep apnea syndrome, congenital hypoventilation syndrome, hypoventilation syndrome due to obesity, syndrome of sudden death of an apparently healthy child, Rett syndrome, spinal cord injury, traumatic brain damage, Chain-Stokes breathing, central congenital hypoventilation syndrome, Prader-Willi syndrome and brain death. In particular, the invention relates to bicyclic amide compounds used to treat these conditions and methods for using these compounds to carry out such treatment.

EA201101162A 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses EA018994B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20664209P 2009-02-02 2009-02-02
PCT/US2010/000255 WO2010087981A2 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses

Publications (2)

Publication Number Publication Date
EA201101162A1 true EA201101162A1 (en) 2012-01-30
EA018994B1 EA018994B1 (en) 2013-12-30

Family

ID=42396261

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101162A EA018994B1 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses

Country Status (12)

Country Link
EP (1) EP2391621A4 (en)
JP (1) JP2012516845A (en)
KR (1) KR20110115139A (en)
CN (1) CN102369201A (en)
AU (1) AU2010208646A1 (en)
BR (1) BRPI1005316A2 (en)
CA (1) CA2751285A1 (en)
EA (1) EA018994B1 (en)
IL (1) IL214392A0 (en)
MX (1) MX2011008060A (en)
SG (1) SG173168A1 (en)
WO (2) WO2010087981A2 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE215079T1 (en) * 1992-07-24 2002-04-15 Univ California DRUGS THAT INCREASE THE SYNAPTIC RESPONSE MEDIATED BY AMPA RECEPTORS
US20020099050A1 (en) * 1993-07-23 2002-07-25 Lynch Gary S. Drugs that enhance synaptic responses mediated by AMPA receptors
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
CN1281335A (en) * 1997-10-27 2001-01-24 科泰克斯药物股份有限公司 Treatment of schizophrenia with ampakines and neuroleptics
US8013003B2 (en) * 2007-05-17 2011-09-06 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
SG163526A1 (en) * 2007-08-10 2010-08-30 Cortex Pharma Inc Bicyclic amides for enhancing glutamatergic synaptic responses

Also Published As

Publication number Publication date
AU2010208646A1 (en) 2011-09-01
WO2010087981A2 (en) 2010-08-05
CA2751285A1 (en) 2010-08-05
SG173168A1 (en) 2011-08-29
WO2010087980A3 (en) 2011-02-24
WO2010087981A3 (en) 2011-03-24
EA018994B1 (en) 2013-12-30
IL214392A0 (en) 2011-09-27
BRPI1005316A2 (en) 2019-09-24
EP2391621A2 (en) 2011-12-07
MX2011008060A (en) 2011-09-09
CN102369201A (en) 2012-03-07
WO2010087980A2 (en) 2010-08-05
EP2391621A4 (en) 2012-07-25
JP2012516845A (en) 2012-07-26
KR20110115139A (en) 2011-10-20

Similar Documents

Publication Publication Date Title
EA200901546A1 (en) DESIGNED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES
EA201000516A1 (en) 3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE and 3-SUBSTITUTE 1,3-Pyrimidine-ONE TO STRENGTHEN GLUTAMATERGIC SYNAPTIC RESPONSES
SG163526A1 (en) Bicyclic amides for enhancing glutamatergic synaptic responses
NZ595625A (en) Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators
EA201390971A1 (en) IMIDAZO [5,1-f] [1,2,4] TRIAZINS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
EA202090043A1 (en) Diazabicyclic substituted imidazopyrimidines and their use
MA32898B1 (en) POSITIVE ALLOSTERIC MODULATORS OF ARYLMETHYLBENZOQUINAZOLINONE M1 RECEPTOR
MX2011011489A (en) Isoxazole-pyridine derivatives.
EP3572417A3 (en) 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
EA200900937A1 (en) COMPOUNDS OF 3-SUBSTITUTED- [1,2,3] BENZOTRIAZINONE FOR STRENGTHENING GLUTAMATERGIC SYNAPTIC RESPONSES
MX2011007774A (en) Isoxazole-isoxazole and isoxazole-isothiazole derivatives.
EA200900925A1 (en) 3-SUBSTITUTE- [1,2,3] -BENZOTRIAZINOUS CONNECTION FOR INCREASING GLUTAMATERIC SYNAPTIC RESPONSES
MX2012010658A (en) Spiro-tetracyclic ring compounds as beta - secretase modulators.
NZ573565A (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
MX2012010657A (en) Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as beta - secretase modulators and their medical use.
MX2011011273A (en) Isoxazole-pyrazole derivatives.
MX2009004071A (en) Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto.
MX2011011477A (en) Isoxazole-pyridazine derivatives.
MY160075A (en) Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
WO2006021000A3 (en) Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i epsilon
NO20080393L (en) Halogenated pyrazolo [1,5-A] pyrimidines, methods, use as GABA-A receptor ligands, compositions and intermediates
JOP20220102A1 (en) Inhibitors of adrenoreceptor adrac2
UY30529A1 (en) 1H-QUINOLIN-4-ONA COMPOUNDS, PROCEDURES, USES AND COMPOSITIONS
EA201101162A1 (en) DERIVATIVES OF BICYCLIC AMIDA FOR STRENGTHENING GLUTAMATERGIC SYNAPTIC RESPONSES
RU2014149123A (en) Phenyltriazole derivative and its use for modulation of the GABAA receptor complex

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU